Johnson & Johnson MedTech Chairman Tim Schmid: Confident in High-End Growth, Cardiovascular to Be Largest Business by Q1 2027
Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid stated the company is confident in achieving the high end of its 5% to 7% operational market-growth range for 2022-2027. He highlighted a portfolio shift towards cardiovascular products, which are expected to become the company's largest and fastest-growing MedTech business by the first quarter of next year, driven by acquisitions like Abiomed and Shockwave.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
stated at the 35th annual CASPA conference held in the US on October 23rd that AI infrastructure investment is facing multiple challenges
-
2
UAE's oil supply rebounded to a record high of 5.3 million barrels per day (bpd) in September
-
3
TREAT Token: An Analysis of the Core Token in the Shiba Inu Ecosystem
-
4
UN and human rights organizations condemn Israeli evictions in Hebron, while Israeli ministers express support.
-
5
Mishaboar posted on X, proposing several measures for the growth of the Dogecoin ecosystem
-
6
Sri Lanka's real estate market is experiencing a luxury property boom
-
7
Bulgarians are voting in a presidential election today
-
8
Al Jazeera: Israel imposes full blockade and military operation in West Bank, potentially impacting Tuesday's general election
-
9
Deutsche Bank noted that the correction in U.S. tech stocks may not be over yet
-
10
Houthis attack Saudi Arabia and Yemen's Aden; Saudi Arabia claims to intercept two missiles targeting Mecca and Medina.
Markets Today
Recommended Reading



